Table 2.
Third-line therapies used in alternate cohort
| Third-line regimens | n (%) |
|---|---|
| Platinum-based combination (eg, DHAP) | 43 (29) |
| Clinical trial | 38 (26) |
| Etoposide-based (eg, CEPP) | 13 (8.9) |
| Anthracycline-based combination (eg, CHOP) | 13 (8.9) |
| Bendamustine-rituximab | 9 (6.2) |
| Lenalidomide-rituximab | 8 (5.4) |
| Gemcitabine-based | 6 (4.1) |
| Ibrutinib | 5 (3.4) |
| IVAC | 3 (2.0) |
| Rituximab monotherapy | 2 (1.3) |
| Other | 6 (4.1) |
| Consolidation after third line | |
| Allogeneic transplant | 10 (6.8) |
| Autologous transplant | 12 (8.2) |
CEPP, cyclophosphamide/etoposide/procarbazine/prednisone; CHOP, cyclophosphamide/doxorubicin/vincristine/prednisone; DHAP; dexamethasone/cytarabine/cisplatin; IVAC, ifosfamide/etoposide/cytarabine.